Lipid Polymer Hybrid Nanoparticles Against Lung Cancer and Their Application As Inhalable Formulation

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2024 Aug 15

PMID 39143915

Authors

Seyedeh Negin Kassaee

Derek Richard

Godwin A Ayoko

Nazrul Islam

Affiliations

Soon will be listed here.

Abstract

Lung cancer is a leading cause of global cancer mortality, often treated with chemotherapeutic agents. However, conventional approaches such as oral or intravenous administration of drugs yield low bioavailability and adverse effects. Nanotechnology has unlocked new gateways for delivering medicine to their target sites. Lipid-polymer hybrid nanoparticles (LPHNPs) are one of the nano-scaled delivery platforms that have been studied to exploit advantages of liposomes and polymers, enhancing stability, drug loading, biocompatibility and controlled release. Pulmonary administration of drug-loaded LPHNPs enables direct lung deposition, rapid onset of action and heightened efficacy at low doses of drugs. In this manuscript, we will review the potential of LPHNPs in management of lung cancer through pulmonary administration.

References

Gandhi S, Roy I . Lipid-Based Inhalable Micro- and Nanocarriers of Active Agents for Treating Non-Small-Cell Lung Cancer. Pharmaceutics. 2023; 15(5). PMC: 10223242. DOI: 10.3390/pharmaceutics15051457. View

Szabova J, Misik O, Fucik J, Mrazova K, Mravcova L, Elcner J . Liposomal form of erlotinib for local inhalation administration and efficiency of its transport to the lungs. Int J Pharm. 2023; 634:122695. DOI: 10.1016/j.ijpharm.2023.122695. View

Mao J, Pillai G, Andrade C, Ligibel J, Basu P, Cohen L . Integrative oncology: Addressing the global challenges of cancer prevention and treatment. CA Cancer J Clin. 2021; 72(2):144-164. DOI: 10.3322/caac.21706. View

Saha T, Quinones-Mateu M, Das S . Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices. Int J Pharm. 2022; 624:122042. PMC: 9296254. DOI: 10.1016/j.ijpharm.2022.122042. View

Xiong Q, Li Y, Zhou K, Chen P, Guo H, Chen L . Optimized fluorodendrimer-incorporated hybrid lipid-polymer nanoparticles for efficient siRNA delivery. Biomater Sci. 2020; 8(3):758-762. DOI: 10.1039/c9bm01738k. View

Fu F, Wang W, Wu L, Wang W, Huang Z, Huang Y . Inhalable Biomineralized Liposomes for Cyclic Ca-Burst-Centered Endoplasmic Reticulum Stress Enhanced Lung Cancer Ferroptosis Therapy. ACS Nano. 2023; 17(6):5486-5502. DOI: 10.1021/acsnano.2c10830. View

Vaidya B, Kulkarni N, Shukla S, Parvathaneni V, Chauhan G, Damon J . Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics. Int J Pharm. 2020; 577:118995. DOI: 10.1016/j.ijpharm.2019.118995. View

Al-Shdefat R, Hailat M, Alshogran O, Dayyih W, Gardouh A, Al Meanazel O . Ribociclib Hybrid Lipid-Polymer Nanoparticle Preparation and Characterization for Cancer Treatment. Polymers (Basel). 2023; 15(13). PMC: 10347058. DOI: 10.3390/polym15132844. View

Schraufnagel D . Lung lymphatic anatomy and correlates. Pathophysiology. 2009; 17(4):337-43. DOI: 10.1016/j.pathophys.2009.10.008. View

10.

Xiroudaki S, Schoubben A, Giovagnoli S, Rekkas D . Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives. Pharmaceutics. 2021; 13(9). PMC: 8467565. DOI: 10.3390/pharmaceutics13091455. View

11.

Watts A, McConville J, Williams 3rd R . Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm. 2008; 34(9):913-22. DOI: 10.1080/03639040802144211. View

12.

Senapati S, Mahanta A, Kumar S, Maiti P . Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018; 3:7. PMC: 5854578. DOI: 10.1038/s41392-017-0004-3. View

13.

Hadinoto K, Sundaresan A, Cheow W . Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm. 2013; 85(3 Pt A):427-43. DOI: 10.1016/j.ejpb.2013.07.002. View

14.

Kaur R, Dennison S, Burrow A, Rudramurthy S, Swami R, Gorki V . Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention. J Nanobiotechnology. 2021; 19(1):19. PMC: 7798018. DOI: 10.1186/s12951-020-00731-1. View

15.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

16.

Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E . In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer. 2019; 146(4):895-905. PMC: 6972582. DOI: 10.1002/ijc.32193. View

17.

Meenach S, Anderson K, Hilt J, McGarry R, Mansour H . High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies. AAPS PharmSciTech. 2014; 15(6):1574-87. PMC: 4245438. DOI: 10.1208/s12249-014-0182-z. View

18.

Parvathaneni V, Shukla S, Kulkarni N, Gupta V . Development and characterization of inhalable transferrin functionalized amodiaquine nanoparticles - Efficacy in Non-Small Cell Lung Cancer (NSCLC) treatment. Int J Pharm. 2021; 608:121038. DOI: 10.1016/j.ijpharm.2021.121038. View

19.

Mangal S, Gao W, Li T, Zhou Q . Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin. 2017; 38(6):782-797. PMC: 5520191. DOI: 10.1038/aps.2017.34. View

20.

Shetty N, Cipolla D, Park H, Zhou Q . Physical stability of dry powder inhaler formulations. Expert Opin Drug Deliv. 2019; 17(1):77-96. PMC: 6981243. DOI: 10.1080/17425247.2020.1702643. View